Ansell Limited (ASX:ANN)
Australia
· Delayed Price · Currency is AUD | Market Cap | 3.66B |
| Revenue (ttm) | 3.01B |
| Net Income (ttm) | 202.99M |
| Shares Out | 139.93M |
| EPS (ttm) | 1.39 |
| PE Ratio | 18.79 |
| Forward PE | 12.64 |
| Dividend | 0.78 (2.94%) |
| Ex-Dividend Date | Feb 23, 2026 |
| Volume | 1,509,653 |
| Average Volume | 473,803 |
| Open | 26.26 |
| Previous Close | 26.52 |
| Day's Range | 26.00 - 26.41 |
| 52-Week Range | 26.03 - 37.54 |
| Beta | 0.61 |
| RSI | 28.46 |
| Earnings Date | Aug 25, 2026 |
About Ansell
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial. The Healthcare segment manufactures and markets solutions, including surgical gloves, single-use and examination gloves, and clean and sterile gloves and garments, as well as consumables for hospitals, surgical centers, dental surgeries, veterinary clinics, first respond... [Read more]
Financial Performance
In fiscal year 2025, Ansell's revenue was $2.00 billion, an increase of 23.71% compared to the previous year's $1.62 billion. Earnings were $101.60 million, an increase of 32.81%.
Financial numbers in USD Financial StatementsNews
Ansell Earnings Call Transcript: H1 2026
Double-digit adjusted EPS growth and record cash flow were achieved despite subdued markets, with tariff costs fully offset by price increases and productivity gains. Guidance is maintained, supported by innovation, strong balance sheet, and ongoing share buybacks.
Ansell Transcript: AGM 2025
Strong FY2025 results were driven by organic growth, successful KBU integration, and productivity gains. The board addressed U.S. tariff risks, labor rights, and sustainability, with ongoing board succession and digital transformation initiatives.
Ansell Earnings Call Transcript: H2 2025
Delivered strong FY 2025 results with 8% organic sales growth, 10% EBIT growth, and adjusted EPS at the top end of guidance. KBU integration exceeded expectations, and a $200M share buyback is planned. FY 2026 guidance anticipates further growth and tariff mitigation.
Ansell Earnings Call Transcript: H1 2025
Double-digit growth in both revenue and profit, driven by strong Healthcare and Industrial segments, successful KBU integration, and productivity gains. EPS guidance was raised, with cost and supply chain risks managed through pricing and operational flexibility.
Ansell Transcript: AGM 2024
The meeting reviewed FY24 results, with industrial growth offsetting healthcare declines and strong cash conversion. Strategic highlights included the Kimberly-Clark PPE acquisition, APIP progress, and advanced sustainability initiatives. Shareholders engaged on governance, capital raising, and legal matters.
Ansell Earnings Call Transcript: H2 2024
Adjusted EPS landed near the top of guidance, driven by record industrial margins and strong cash flow, while healthcare recovered as destocking eased. The KBU acquisition is integrating well, with modest FY25 EPS impact expected, and sustainability leadership was recognized by top agencies.
Ansell Transcript: M&A Announcement
Ansell Earnings Call Transcript: H1 2024
Ansell Transcript: AGM 2023
Ansell Earnings Call Transcript: H2 2023
Ansell Earnings Call Transcript: Q4 2023
Ansell Earnings Call Transcript: H1 2023
Ansell Transcript: ESG Update
Ansell Earnings Call Transcript: H2 2022
Ansell Earnings Call Transcript: H1 2022
Ansell Earnings Call Transcript: H1 2022
Ansell Transcript: AGM 2021
Ansell Earnings Call Transcript: H2 2021
PPE Manufacturer Ansell Still Trading at a Nice Valuation
Imagine investing in a company that made rubber gloves, facemasks and Hazmat suits during the Covid-19 pandemic. It exists!